Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05132712
Other study ID # 105471
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 1, 2021
Est. completion date September 30, 2022

Study information

Verified date November 2021
Source Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic kidney disease (CKD) is one of the leading health problems imbibing a major portion of health budget worldwide. The global prevalence of CKD is estimated to be 13.4% with approximately 5 to 7 million people needing renal replacement therapy. There is lack of epidemiological surveys regarding CKD but it is estimated to be around 5% and nearly half of them are diabetic. In Pakistan most of the patients undergo hemodialysis as mode of renal replacement as renal transplant centers are few and over burdened. Therefore, a good vascular access for hemodialysis is vital for CKD patients. A functioning arterio-venous fistula (AVF) improves quality of life and morbidity. However, access failure remains a major problem in patients of CKD accounting for third most common cause of admission. There are various options for attaining vascular access but AVF remains the most reliable with less morbidity and better overall patency rate. However, the AVF has its own limitation and has overall patency rate of 50-70% at 1 year and 30-40% at 2 years. This outcome indicates that strategies to prevent occlusion by altering modifiable risk factors are suboptimal and warrant further research. Patients of CKD often have associated cardiovascular diseases as Ischemic heart disease, left ventricular failure and angina. They are often taking cardio-protective medicines as antiplatelets, angiotensin converting enzymes and calcium channel blockers. Intimal hyperplasia has been shown to be the most important cause of AVF failures.2 Angiotensin II promotes vascular smooth muscle proliferation through various growth factors. Various experimental models have clearly depicted that ACE inhibitors effectively stop smooth muscle growth and intimal hyperplasia in vessel walls. Literature review shows conflicting results in terms of AVF patency when ACE inhibitors are used in conjunction. A study by Jackson RS and colleagues showed that ACE inhibitor were associated with reduced hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.16-0.76; P = .008). Whereas, another study showed no role of ACE inhibitors in preventing graft failure. The possible explanation can be study designs as most studies were retrospective and effects of possible confounders. Moreover, there is lack of research in Pakistan to see the effects of pharmacological drugs on primary patency of AVF among CKD patients. The rationale of this study is to effectively establish the role of ACE inhibitors in achieving primary patency of AV fistulas while reducing the number of confounders. This will be the first randomized controlled trial conducted in Pakistan. The primary outcome is AVF patency at one year. Secondary outcomes will include graft complications and graft maturation time after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 79 Years
Eligibility Inclusion Criteria: All patients who were undergoing Hemodialysis or were intended to start HD within three months between the age of 20 years to 70 years were included in the study Exclusion Criteria: - Age less than 20 years or more than 79 years - In patients who are not expected to start dialysis in next 3 months - Non-consenting patients - Patients with diagnosed carcinoma whose life expectancy is less than a year. - Patients with un-controlled hypertension on multiple regimes of antihypertensive - Patients allergic to ACE inhibitors

Study Design


Intervention

Drug:
Losartan Potassium
ACE inhibitor
multi-vitamins
placebo drug

Locations

Country Name City State
Pakistan Anas Bin Saif Rawalpindi Punjab

Sponsors (1)

Lead Sponsor Collaborator
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary primary patency at one year 1 year
Secondary graft complications 1 year
Secondary maturation time of fistula 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Active, not recruiting NCT04054128 - Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients Phase 4
Completed NCT02297308 - A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications N/A
Completed NCT01446263 - RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention (RADIAL-CABG) Trial Phase 3
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Completed NCT02200458 - Near-infrared Software Performance Study N/A
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A
Recruiting NCT04077762 - Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH) N/A
Completed NCT05982366 - Feasibility and Safety of the Routine Distal Transradial Approach N/A
Completed NCT05101720 - Ultrasound Guided Axillary Access vs Standard Fluoroscopic Technique for Cardiac Lead Implantation: ZEROFLUOROAXI TRIAL N/A
Terminated NCT03879824 - Radial Versus Femoral Secondary Access During TAVI N/A
Recruiting NCT05741866 - Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs) N/A
Completed NCT05093699 - Dual-plane Ultrasound Imaging During Vascular Access Procedures N/A
Recruiting NCT02449798 - Prospective Feasibility Trial of AccuCath 2.25" BC Placed in Difficult Access Patients in the Emergency Department N/A
Active, not recruiting NCT02808208 - Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure Phase 1/Phase 2
Completed NCT04409418 - Blood Sampling Functionality of Extended Dwell Catheters N/A
Recruiting NCT04472221 - Arterio-arterial Vascular Access as a Novel Technique for Treatment of Venous Hypertention With Arterio-venous Vascular Access N/A
Completed NCT02558153 - RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula N/A
Completed NCT01927185 - Long-versus Short-Axis Ultrasound Guidance for Subclavian Vein Cannulation N/A
Terminated NCT00914069 - Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter N/A